Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
RationaleDronabinol (Δ9tetrahydrocannabinol) is approved for HIV-related anorexia, yet, little is known about its effects in HIV-positive marijuana smokers. HIV-negative marijuana smokers require higher than recommended dronabinol doses to experience expected effects.ObjectivesEmploying a within-subjects, double-blind, placebo-controlled design, we assessed the effects of repeated high-dose dronabinol in HIV-positive marijuana smokers taking antiretroviral medication.MethodsParticipants (N = 7), who smoked marijuana 4.2 ± 2.3 days/week, resided in a residential laboratory for two 16-day stays, receiving dronabinol (10 mg QID) in one stay and placebo in the other. Efficacy was assessed with objectively verified food intake and body weight. Tolerability was measured with sleep, subjective, and cognitive assessments. For analyses, each inpatient stay was divided into two phases, days 1–8 and 9–16; we compared dronabinol’s effects with placebo in each 8-day phase to investigate tolerance.ResultsDespite sustained increases in self-reported food cravings, dronabinol only increased caloric intake in the initial 8 days of dosing. Similarly, sleep quality was improved only in the first 8 days of dosing. Dronabinol’s mood-enhancing effects were sustained across the 16-day inpatient stay. Dronabinol was well tolerated, causing few negative subjective or cognitive effects.ConclusionsIn HIV-positive marijuana smokers, high dronabinol doses safely and effectively increased caloric intake. However, repeated high-dose dronabinol appeared to result in selective tolerance to these effects. These findings indicate that HIV-positive individuals who smoke marijuana may require higher dronabinol doses than are recommended by the FDA. Future research to establish optimal dosing regimens, and reduce the development of tolerance, is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., & Shepard, K. V. (1995) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)00117-4 · Cited by 504 · cited 12×
“…low doses of dronabinol (2.5 mg daily to 5 mg BID) increased self-reported appetite relative to placebo in patients with HIV or AIDS (Beal et al. 1995; Beal et al. 1997), neither caloric intake (Struwe et al. 1993) nor weight (Beal et al. 1995; Struwe et al. 1993) increases reached significance.”
BackgroundInfluentialAbrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., Benowitz, N. L., Bredt, B. M., Kosel, B., Aberg, J. A., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00008 · Cited by 238 · cited 2×
“…Bedi : R. W. Foltin : E. W. Gunderson : J. Rabkin : C. L. Hart : S. D. Comer : S. K. Vosburg :M. Haney (*) Division on Substance Abuse, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA e-mail: mh235@columbia.edu effects (Abrams 2000; Abrams et al. 2003).”
BackgroundInfluentialCannabis use in HIV for pain and other medical symptoms
Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., & Holdcroft, A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.011 · Cited by 208 · cited 2×
“There is a high incidence of marijuana use among HIV-positive people, with one quarter (Prentiss et al. 2004) to one third (Dansak 1997; Furler et al. 2004 ;W are et al. 2003; Woolridge et al. 2005 ) of HIV/AIDS patients estimated to be current marijuana users, many reporting using the drug for medicinal purposes.”
BackgroundDronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep
Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31811ed205 · Cited by 184
Self-citationDronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood
Haney, M., Rabkin, J., Gunderson, E., & Foltin, R. W. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2242-2 · Cited by 126 · cited 20×
“One outpatient study we conducted indicated that single dronabinol doses increase caloric intake over a seven-hour period only in individuals with significant muscle loss (Haney et al. 2005).”
BackgroundMethodResultInfluentialSelf-citationVariability in subjective responses to cocaine: initial experiences of college students
Davidson, E. S., Finch, J. F., & Schenk, S. (1993) · Addictive Behaviors · doi:10.1016/0306-4603(93)90062-e · Cited by 86 · cited 1×
“Given substantial inter-individual variability ( Davidson and Schenk 1994; Kirk and de Wit 1999; Sachse-Seeboth et al. 2009) in cannabinoid effects, further studies examining the efficacy of different delivery methods and doses of medical cannabinoids in clinically relevant patient groups is critical to inform the deb…”
Background
Cited by
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Bedi, G., Cooper, Z. D., & Haney, M. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00427.x · Cited by 83
Self-citationHaney, M., Ramesh, D., Glass, A., Pavlicova, M., Bedi, G., & Cooper, Z. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.108 · Cited by 73
Self-citationSpanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
Metadata
- Authors
- Bedi, G., Foltin, R. W., Gunderson, E. W., Rabkin, J., Hart, C. L., Comer, S. D., Vosburg, S. K., & Haney, M.
- Venue
- Psychopharmacology
- Published
- 2010-09-08
- Volume
- 212
- Issue
- 4
- Pages
- 675-686
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2005664616
- Cited by
- 77
- References
- 6
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. https://app.cochat.ai/papers/10.1007/s00213-010-1995-4
- The paper
- Bedi, G., Foltin, R. W., Gunderson, E. W., Rabkin, J., Hart, C. L., Comer, S. D., Vosburg, S. K., & Haney, M. (2010). Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology. https://doi.org/10.1007/s00213-010-1995-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.